Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions

Dentons advised Immunic, Inc. on its private placement financing of up to US$400 million, including US$200 million in initial proceeds and the potential for an additional US$200 million. The financing is expected to support the completion of Immunic’s Phase III clinical trials and its transition to a commercial organization, advancing the company’s long-term growth and strategic objectives. Dentons was pleased to support Immunic on these transactions with a Venture Technology team led by Ilan Katz, Grant Levine, Zachary Weiss, and Madeline Hunter in New York. The post Dentons Advises Immunic, Inc. on Private Placement and Royalty Transactions appeared first on Legal Desire Media and Insights .